Dr. Mengchao Wei | Venous thromboembolism | Best Researcher Award
Dr. Mengchao Wei, Peking Union Medical College Hospital, China
Dr. Mengchao Wei is a physician at Peking Union Medical College Hospital, China, specializing in Urology. He graduated with a Doctor’s degree from Sun Yat-sen University in 2019. Since joining PUMCH in 2021, Dr. Wei has focused on optimizing perioperative management for urologic surgeries. He developed a predictive model for venous thromboembolism risk post-surgery, now integrated into clinical practice. Dr. Wei has published 10 journal articles in SCI and Scopus indexed journals. His research aims to improve patient safety and surgical outcomes, making significant contributions to the field of urologic surgery.
Author Profile
šEarly Academic Pursuits:Ā
Dr. Mengchao Wei graduated with a Doctor’s degree from Sun Yat-sen University in 2019. His academic journey laid the foundation for his current work, particularly in the field of Urology, where he became deeply involved in understanding the nuances of perioperative management in urologic surgeries. His comprehensive training and early research set him on a path to clinical excellence and innovation.
āļøProfessional Endeavors and Contributions:Ā
Since 2021, Dr. Wei has been practicing as a Physician at Peking Union Medical College Hospital, where his focus lies in the optimization of perioperative management in urologic surgeries. His clinical work has had a direct impact on improving patient care and the efficiency of surgical outcomes. Dr. Wei’s contributions include the development of a predictive model for venous thromboembolism risk following urologic surgeries, which has been implemented in real-world clinical practice to enhance patient safety.
š¬Research Focus and Innovations on Venous thromboembolism:
Dr. Wei’s research centers on perioperative management within urology, particularly concerning venous thromboembolism (VTE) risk. His predictive model for VTE risk, now utilized in clinical settings, showcases his ability to translate research into tangible, life-saving outcomes. While his citation index stands at 10, his work continues to gain attention in the medical community. He has published 10 journals in esteemed databases such as SCI and Scopus, reinforcing his status as a respected figure in urologic research.
šImpact and Influence:Ā
Dr. Wei’s contributions have not only benefited his hospital but also shaped the way urologic surgeries are managed perioperatively. By providing a tool that enhances clinical decision-making, he directly improves surgical outcomes, patient safety, and overall healthcare efficiency. His work has influenced peers, setting a new standard in the field of urology.
šAcademic Citations:
Dr. Wei has an impressive citation index of 10, a reflection of the growing recognition of his work and the clinical value it brings. His research continues to receive acknowledgment in relevant medical journals, contributing to the advancement of perioperative care in urology.
šLegacy and Future Contributions:Ā
Dr. Wei’s research and innovations indicate a promising future in the field of urology. He is committed to enhancing perioperative management for urologic surgeries and advancing clinical practices. Moving forward, his aim is to refine predictive models and further contribute to patient safety and surgical excellence.
šConclusion:
Dr. Mengchao Wei’s work at Peking Union Medical College Hospital has made a significant impact on perioperative management in urologic surgeries. His predictive model for venous thromboembolism risk has been successfully integrated into clinical practice, improving patient outcomes and safety. With 10 journal publications in SCI and Scopus indexed journals, Dr. Wei is recognized as a dedicated and innovative physician. His contributions are shaping the future of urologic surgery. As he continues to push the boundaries of medical research, his work promises to enhance the quality of care and patient safety worldwide.
Top Notable PublicationsĀ
A nomogram predicting the risk of venous thromboembolism in patients following urologic surgeries
Authors: Mengchao Wei
Journal: Scientific Reports
Year: 2025
The role of antimicrobial prophylaxis in laparoscopic nephrectomy for renal cell carcinoma
Authors: Mengchao Wei
Journal: BMC Urology
Year: 2024
Comparison of AirSeal versus conventional insufflation system for retroperitoneal robot-assisted laparoscopic partial nephrectomy: a randomized controlled trial
Authors: Mengchao Wei
Journal: World Journal of Urology
Year: 2024
Surgery or external beam radiation for solitary small hepatocellular carcinoma
Authors: Mengchao Wei
Journal: Journal of Cancer Research and Therapeutics
Year: 2023
Adjuvant Sorafenib Following Radiofrequency Ablation for Early-Stage Recurrent Hepatocellular Carcinoma With Microvascular Invasion at the Initial Hepatectomy
Authors: Mengchao Wei
Journal: Frontiers in Oncology
Year: 2022
Role of Preoperational Imaging Traits for Guiding Treatment in Single ā¤ 5 cm Hepatocellular Carcinoma
Authors: Mengchao Wei
Journal: Annals of Surgical Oncology
Year: 2022
The Combination of Radiation Therapy and Immunotherapy Is Effective and Well-Tolerated for Unresectable Biliary Tract Cancer
Authors: Mengchao Wei
Journal: International Journal of Radiation Oncology, Biology, Physics
Year: 2022
Prognostic Role of Time to Surgery in Hepatocellular Carcinoma at Barcelona Clinic Liver Cancer Stage 0-A
Authors: Mengchao Wei
Journal: Annals of Surgical Oncology
Year: 2020
Radiofrequency ablation plus nucleotide analogues for hepatitis B virus-related hepatocellular carcinoma: a cost-effectiveness analysis
Authors: Mengchao Wei
Journal: American Journal of Translational Research
Year: 2018
Sorafenib versus Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
Authors: Mengchao Wei
Journal: BMC Cancer
Year: 2018